Clinical Potential of Minocycline for Neurodegenerative Disorders
Open accessAbstract
Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntington's disease, amyotrophic lateral sclerosis and Parkinson's disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to the launching of various clinical trials. The present review summarizes the available data supporting the clinical testing of minocycline for these neurodegenerative disorders. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Minocycline efficiently crosses the BBB.
“Thanks to the ability to efficiently cross the BBB, minocycline is considered neuroprotective for a variety of neurological conditions, including PD [251,252,253,254,255,256,257].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [255]
Minocycline is considered neuroprotective for a variety of neurological conditions, including PD.
“Thanks to the ability to efficiently cross the BBB, minocycline is considered neuroprotective for a variety of neurological conditions, including PD [251,252,253,254,255,256,257].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [255]
The citation lists haven’t been fetched yet
References 112 · Cited by 157
- Authors
- BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M.
- Affiliations
- Université Libre de Bruxelles (BE)
- Corresponding author
- BLUM, D
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 17
- Issue
- 3
- Pages
- 359-366
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2046096689
- Cited by
- 157
- References
- 112
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 8 · 2019: 5 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 5 · 2014: 8 · 2013: 14 · 2012: 8
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- green
- doaj.org
- Licence
- Locations
- Neurobiology of Disease (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Hereditary Disease Foundation
- Universitaire Stichting
- Fonds De La Recherche Scientifique - FNRS
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- minocycline, neuroprotection, neurorestoration, neurodegenerative diseases, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, neuroinflammation, apoptosis, clinical trials, tetracycline antibiotics, combination therapy
- MeSH terms
- Animals, Humans, Huntington Disease, Inflammation, Minocycline, Parkinson Disease, Motor Neuron Disease, Apoptosis, Neuroprotective Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
